Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vendeavour Group is a Czech holding and investment group that operates through a portfolio of manufacturing, trading, and growth companies, with stated focus areas spanning food, medical technology, life sciences, and sustainability. Its healthcare exposure appears to be centered on commercial-stage businesses rather than drug development, including Promedeus, which supplies advanced medical equipment to hospitals and clinics, and activities serving allergy patients. The group also manages the VENDEAVOUR Private Equity Fund SICAV, a qualified-investor fund used to hold and develop portfolio companies. Based on publicly available information, Vendeavour is not a clinical-stage biotech or pharmaceutical developer; it is better characterized as a diversified investment and operating group with meaningful healthcare and medical-technology interests.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vendeavour Group.